


## Exatecan Intermediate 7

<b>Cat. No.:</b>	HY-45157		
<b>CAS No.:</b>	182182-32-7		
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>13</sub> FN <sub>2</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	264.25		
<b>Target:</b>	ADC Cytotoxin; Topoisomerase		
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (378.43 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.7843 mL	18.9215 mL	37.8429 mL
	5 mM	0.7569 mL	3.7843 mL	7.5686 mL
	10 mM	0.3784 mL	1.8921 mL	3.7843 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Exatecan Intermediate 7 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC<sub>50</sub> value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 7 can be used to synthesize Antibody-Drug Conjugates (ADCs).

#### IC<sub>50</sub> & Target

Camptothecins

### REFERENCES

- [1]. Kamihara, et al. Aminotetralone derivatives and process for producing the same. World Intellectual Property Organization, WO9626181 A1 1996-08-29.
- [2]. Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776-82.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA